Survivin’ acute myeloid leukaemia—a personalised target for inv(16) patients

Greiner, Jochen; Brown, Elliott; Bullinger, Lars; Hills, Robert K.; Morris, Vanessa; Döhner, Hartmut; Mills, Ken I.; Guinn, Barbara Ann

doi:10.3390/ijms221910482

All Outputs (4)

Molecular Mechanisms and Therapies of Myeloid Leukaemia (2022)
Journal Article
Brown, E., & Guinn, B. A. (2022). Molecular Mechanisms and Therapies of Myeloid Leukaemia. International Journal of Molecular Sciences, 23(11), Article 6251. https://doi.org/10.3390/ijms23116251

miRNA expression in acute myeloid leukaemia: new targets for therapy? (2022)
Journal Article
Fletcher, D., Brown, E., Javadala, J., Uysal-Onganer, P., & Guinn, B. (in press). miRNA expression in acute myeloid leukaemia: new targets for therapy?. eJHaem, https://doi.org/10.1002/jha2.441

Recent studies have shown that short non-coding RNAs, known as microRNAs (miRNAs) and their dysregulation, are implicated in the pathogenesis of acute myeloid leukaemia (AML). This is due to their role in the control of gene expression in a variety o... Read More about miRNA expression in acute myeloid leukaemia: new targets for therapy?.

microRNA expression in acute myeloid leukaemia: New targets for therapy? (2022)
Journal Article
Fletcher, D., Brown, E., Javadala, J., Uysal-Onganer, P., & Guinn, B. (2022). microRNA expression in acute myeloid leukaemia: New targets for therapy?. eJHaem, 3(3), 596-608. https://doi.org/10.1002/jha2.441

Recent studies have shown that short non-coding RNAs, known as microRNAs (miRNAs) and their dysregulation, are implicated in the pathogenesis of acute myeloid leukaemia (AML). This is due to their role in the control of gene expression in a variety o... Read More about microRNA expression in acute myeloid leukaemia: New targets for therapy?.

Survivin’ acute myeloid leukaemia—a personalised target for inv(16) patients (2021)
Journal Article
Greiner, J., Brown, E., Bullinger, L., Hills, R. K., Morris, V., Döhner, H., …Guinn, B. A. (2021). Survivin’ acute myeloid leukaemia—a personalised target for inv(16) patients. International Journal of Molecular Sciences, 22(19), Article 10482. https://doi.org/10.3390/ijms221910482

Abstract: Despite recent advances in therapies including immunotherapy, patients with acute myeloid leukaemia (AML) still experience relatively poor survival rates. The Inhibition of Apoptosis (IAP) family member, survivin, also known by its gene and... Read More about Survivin’ acute myeloid leukaemia—a personalised target for inv(16) patients.